Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06268886 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

A Phase 2 study of Alzheimer Disease, Early Onset, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 2
Development phase
310
Enrollment target
20
Study locations

NCT06268886 is a Phase 2 study of Alzheimer Disease, Early Onset that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 310 participants, below the 1,460-participant average among 11 other Alzheimer Disease, Early Onset trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06268886, a Phase 2 study of Alzheimer Disease, Early Onset, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
310 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.

Conditions Studied

Alzheimer Disease, Early Onset

Interventions

  • OTHER Placebo
  • DRUG BMS-986446

Study Locations (20)

California

  • Local Institution - 0164 - Encino
  • Local Institution - 0139 - Fullerton
  • Local Institution - 0191 - Irvine
  • Local Institution - 0234 - Long Beach
  • Local Institution - 0142 - Los Alamitos
  • Local Institution - 0037 - Napa
  • Local Institution - 0209 - Sacramento
  • Local Institution - 0052 - San Francisco
  • Local Institution - 0137 - Santa Ana
  • Local Institution - 0046 - Sherman Oaks

Arizona

  • Local Institution - 0068 - Chandler
  • Local Institution - 0102 - Gilbert
  • Local Institution - 0019 - Phoenix
  • Local Institution - 0018 - Scottsdale
  • Local Institution - 0026 - Scottsdale
  • Local Institution - 0077 - Tucson
  • Local Institution - 0038 - Tucson

Connecticut

  • Local Institution - 0106 - Danbury
  • Local Institution - 0148 - New Haven
  • Local Institution - 0056 - New Haven

Trial Details

FieldValue
Enrollment Target 310 participants
Start Date 2024-03-20
Est. Completion 2027-03-18
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06268886

The ClinicalTrials.gov registry entry for NCT06268886 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,460-participant average among 11 other Alzheimer Disease, Early Onset trials with a reported enrollment target (79% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease, Early Onset appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06268886 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06268886 about?

NCT06268886 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease". The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.

What is the current status of trial NCT06268886?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2024-03-20. Estimated completion is 2027-03-18.

What conditions does trial NCT06268886 study?

This clinical trial studies the following conditions: Alzheimer Disease, Early Onset.

What interventions are being tested in trial NCT06268886?

The interventions under investigation include: Placebo (OTHER), BMS-986446 (DRUG).

Who is sponsoring clinical trial NCT06268886?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06268886 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease, Early Onset

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease, Early Onset

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.